Search

Beam Therapeutics Inc

Open

SectorGezondheidszorg

24.11 1.01

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.87

Max

24.91

Belangrijke statistieken

By Trading Economics

Inkomsten

-28M

-123M

Verkoop

-31M

490K

EPS

-1.18

Winstmarge

-25,036.327

Werknemers

540

EBITDA

-36M

-125M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+118.01% upside

Dividenden

By Acuity

Volgende Winsten

2 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

398M

3.1B

Vorige openingsprijs

23.1

Vorige sluitingsprijs

24.11

Nieuwssentiment

By Acuity

70%

30%

297 / 339 Rangschikking in Healthcare

Beam Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 sep 2026, 23:06 UTC

Correlated Moves

Beam Therapeutics shares are higher in after-market trading, likely influenced by a rise in CRISPR Therapeutics following a narrower-than-expected U.S. budget deficit.

10 sep 2026, 23:11 UTC

Beam Therapeutics Inc shares declined in after-market trading, marking the fourth consecutive session of losses and closing significantly below their 20-day moving average.

9 sep 2026, 23:06 UTC

News

Beam Therapeutics shares are trading higher in after-market hours following a presentation at Citigroup's Biopharma Summit, highlighting advancements in its pipeline.

8 sep 2026, 20:03 UTC

News
Social Media
Event

Beam Therapeutics shares are lower despite presenting promising clinical data for BEAM-302 therapy at the European Respiratory Society Congress, amid regulatory concerns.

4 sep 2026, 23:00 UTC

Beam Therapeutics Inc shares are trading higher in after-market hours, continuing a steady increase since Friday's close amid mixed economic signals.

1 sep 2026, 19:36 UTC

News
Social Media

Beam Therapeutics appointed Eric Foster as chief commercial officer. Shares are trading lower despite the leadership change amid preparations for a 2027 product launch.

31 aug 2026, 19:16 UTC

Beam Therapeutics Inc. shares are trading roughly flat, with no specific news identified. The stock remains above its 20-day moving average.

28 aug 2026, 23:06 UTC

Beam Therapeutics Inc. shares are higher in after-market trading, advancing since Friday's close and positioned above its 20-day moving average.

27 aug 2026, 23:02 UTC

Beam Therapeutics Inc. shares are roughly flat in after-market hours with no specific news identified. The stock remains above its 20-day moving average.

26 aug 2026, 23:51 UTC

Beam Therapeutics Inc shares are higher in after-market hours, reflecting a broadly positive market trend. The stock is near the upper end of its one-month range.

25 aug 2026, 20:07 UTC

News
Social Media

HC Wainwright reiterated its Buy rating on Beam Therapeutics, maintaining a $80 price target. Shares are gaining amid positive sentiment and elevated call activity.

24 aug 2026, 20:06 UTC

Beam Therapeutics Inc shares are lower today amid rising oil prices and geopolitical tensions, with no specific news identified to explain the decline.

21 aug 2026, 23:31 UTC

Beam Therapeutics Inc. shares gained in after-market trading, reflecting broader market recovery as traders engaged in bargain hunting following a recent downturn.

20 aug 2026, 22:16 UTC

Beam Therapeutics Inc. shares advanced in after-market trading, remaining above the 20-day moving average and near the upper end of their one-month range.

19 aug 2026, 23:06 UTC

Beam Therapeutics Inc. shares are higher in after-market trading, remaining above the 20-day moving average and near the upper end of their one-month range.

18 aug 2026, 19:16 UTC

Correlated Moves

Shares of Beam Therapeutics are lower today, having declined since Monday amid broader small-cap losses and rising U.S. Treasury yields.

14 aug 2026, 19:36 UTC

Beam Therapeutics is trading higher during Friday's session, recovering from an earlier dip. No specific news has been identified to explain the price action.

13 aug 2026, 23:01 UTC

Beam Therapeutics Inc. shares are higher in after-market trading, reflecting notable upward momentum since Thursday's close, despite no specific news identified.

12 aug 2026, 20:06 UTC

Beam Therapeutics Inc. shares are lower today, continuing a trend of declines since Tuesday's close amid broader market uncertainties and lower U.S. Treasury yields.

11 aug 2026, 23:06 UTC

Beam Therapeutics shares are higher in after-market trading, following a session peak. No specific news was identified to explain the price movement.

5 aug 2026, 19:52 UTC

Correlated Moves

Beam Therapeutics Inc is trading lower as broader market sentiment weakens. The decline follows disappointing ADP employment data, which missed expectations significantly.

4 aug 2026, 23:06 UTC

Beam Therapeutics Inc. shares are lower in after-market hours, following a session low shortly after the open, despite three consecutive higher daily closes.

3 aug 2026, 19:16 UTC

Correlated Moves
News

Beam Therapeutics is rising amid a broader market rally, with a market cap of $2.64 billion and $1.2 billion in liquidity to support operations.

31 jul 2026, 19:16 UTC

Correlated Moves

Beam Therapeutics shares are lower, reflecting a decline in first-quarter results and broader sector weakness. The stock remains near the lower end of its one-month range.

30 jul 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-hours trading, advancing since Thursday's close, despite remaining below the 20-day moving average.

29 jul 2026, 22:51 UTC

Beam Therapeutics shares are lower in after-market hours following a volatile session, amid broader market uncertainty after the Federal Reserve's interest rate decision.

28 jul 2026, 23:51 UTC

Beam Therapeutics Inc shares are lower in after-market trading, experiencing unusual volatility amid broader market declines and positioned below its 20-day moving average.

27 jul 2026, 23:06 UTC

Beam Therapeutics Inc shares are higher in after-market hours, despite a broader decline in trading. No specific news was identified to explain the increase.

24 jul 2026, 19:26 UTC

Event
Correlated Moves

Beam Therapeutics is declining today, reflecting broader market trends, with the Russell 2000 Index down. The stock remains below its 20-day moving average.

23 jul 2026, 09:51 UTC

News

Beam Therapeutics is higher in pre-market trading, driven by significant upcoming clinical milestones, including the global BEAM-302 trial and an FDA application for risto-cel.

Peer Vergelijking

Prijswijziging

Beam Therapeutics Inc Prognose

Koersdoel

By TipRanks

118.01% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 52.3 USD  118.01%

Hoogste 80 USD

Laagste 26 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Beam Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

11 ratings

10

Buy

1

Hold

0

Sell

Sentiment

By Acuity

297 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
help-icon Live chat